Chimeric Therapeutics Limited (CHM.AX)
AUD 0.01
(0.0%)
AUD 0.01
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 15.27 Million AUD | -31.74% |
| 2023 | 22.37 Million AUD | -35.85% |
| 2022 | 34.87 Million AUD | -4.45% |
| 2021 | 36.5 Million AUD | 36504760.0% |
| 2020 | 100.00 AUD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 15.27 Million AUD | -42.77% |
| 2024 Q2 | 26.68 Million AUD | 0.0% |
| 2024 Q1 | 26.68 Million AUD | -25.37% |
| 2024 FY | 15.27 Million AUD | -31.74% |
| 2024 Q4 | 15.27 Million AUD | 0.0% |
| 2023 Q1 | 22.51 Million AUD | -35.44% |
| 2023 Q4 | 35.76 Million AUD | 59.83% |
| 2023 Q3 | 22.37 Million AUD | -0.64% |
| 2023 FY | 22.37 Million AUD | -35.85% |
| 2023 Q2 | 22.51 Million AUD | 0.0% |
| 2022 FY | 34.87 Million AUD | -4.45% |
| 2022 Q3 | 34.87 Million AUD | 24.18% |
| 2022 Q2 | 28.08 Million AUD | 0.0% |
| 2022 Q1 | 28.08 Million AUD | -23.06% |
| 2022 Q4 | 34.87 Million AUD | 0.0% |
| 2021 Q1 | 13.79 Million AUD | 0.0% |
| 2021 FY | 36.5 Million AUD | 36504760.0% |
| 2021 Q4 | 36.5 Million AUD | 0.0% |
| 2021 Q3 | 36.5 Million AUD | 164.68% |
| 2021 Q2 | 13.79 Million AUD | 0.0% |
| 2020 FY | 100.00 AUD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AdAlta Limited | 5.57 Million AUD | -174.056% |
| Acrux Limited | 8.96 Million AUD | -70.402% |
| Actinogen Medical Limited | 21.31 Million AUD | 28.335% |
| AnteoTech Limited | 9.38 Million AUD | -62.806% |
| Argenica Therapeutics Limited | 16.37 Million AUD | 6.743% |
| Arovella Therapeutics Limited | 13.28 Million AUD | -14.968% |
| Anatara Lifesciences Ltd | 1.67 Million AUD | -813.782% |
| Alterity Therapeutics Limited | 19.22 Million AUD | 20.551% |
| Amplia Therapeutics Limited | 14.84 Million AUD | -2.883% |
| Avecho Biotechnology Limited | 7.31 Million AUD | -108.669% |
| Bio-Gene Technology Limited | 3.15 Million AUD | -383.39% |
| Biome Australia Limited | 8.27 Million AUD | -84.53% |
| Biotron Limited | 493.47 Thousand AUD | -2995.015% |
| Botanix Pharmaceuticals Limited | 112.46 Million AUD | 86.42% |
| BTC Health Limited | 5.14 Million AUD | -196.635% |
| CSL Limited | 56.93 Billion AUD | 99.973% |
| Clarity Pharmaceuticals Ltd | 154.62 Million AUD | 90.123% |
| Clinuvel Pharmaceuticals Limited | 231.12 Million AUD | 93.392% |
| Cynata Therapeutics Limited | 8.38 Million AUD | -82.077% |
| Dimerix Limited | 32.07 Million AUD | 52.388% |
| EZZ Life Science Holdings Limited | 25.55 Million AUD | 40.227% |
| Hexima Limited | 2.26 Million AUD | -573.122% |
| Island Pharmaceuticals Limited | 2.56 Million AUD | -495.567% |
| Immuron Limited | 15.54 Million AUD | 1.78% |
| Immutep Limited | 147.44 Million AUD | 89.642% |
| Imugene Limited | 151.39 Million AUD | 89.912% |
| Invex Therapeutics Ltd | 6.12 Million AUD | -149.559% |
| Memphasys Limited | 12.43 Million AUD | -22.872% |
| Nanollose Limited | 241.95 Thousand AUD | -6212.499% |
| Neuren Pharmaceuticals Limited | 247.97 Million AUD | 93.841% |
| Noxopharm Limited | 6.78 Million AUD | -125.143% |
| NeuroScientific Biopharmaceuticals Limited | 5.43 Million AUD | -180.97% |
| Nyrada Inc. | 5.9 Million AUD | -158.549% |
| Orthocell Limited | 26.61 Million AUD | 42.615% |
| PharmAust Limited | 11.12 Million AUD | -37.289% |
| Patrys Limited | 4.16 Million AUD | -267.004% |
| Paradigm Biopharmaceuticals Limited | 27.39 Million AUD | 44.239% |
| Proteomics International Laboratories Limited | 10.87 Million AUD | -40.441% |
| Prescient Therapeutics Limited | 20.39 Million AUD | 25.105% |
| PYC Therapeutics Limited | 91.23 Million AUD | 83.26% |
| Race Oncology Limited | 20.22 Million AUD | 24.497% |
| Radiopharm Theranostics Limited | 72.03 Million AUD | 78.798% |
| Recce Pharmaceuticals Ltd | 6.36 Million AUD | -139.781% |
| Starpharma Holdings Limited | 36.81 Million AUD | 58.513% |
| Telix Pharmaceuticals Limited | 398.3 Million AUD | 96.165% |
| Tissue Repair Ltd | 19.38 Million AUD | 21.23% |
| Zelira Therapeutics Limited | 5.18 Million AUD | -194.654% |